Matches in Wikidata for { <http://www.wikidata.org/entity/Q90628323> ?p ?o ?g. }
- Q90628323 description "artículu científicu espublizáu en payares de 2019" @default.
- Q90628323 description "im November 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q90628323 description "scientific article published on 01 November 2019" @default.
- Q90628323 description "wetenschappelijk artikel" @default.
- Q90628323 description "наукова стаття, опублікована 1 листопада 2019" @default.
- Q90628323 name "Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohor" @default.
- Q90628323 name "Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohor" @default.
- Q90628323 type Item @default.
- Q90628323 label "Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohor" @default.
- Q90628323 label "Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohor" @default.
- Q90628323 prefLabel "Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohor" @default.
- Q90628323 prefLabel "Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohor" @default.
- Q90628323 P1433 Q90628323-DBCD1137-CBD6-4195-9D10-B0AD37012796 @default.
- Q90628323 P1476 Q90628323-10832BC6-B96C-44C7-B73D-89C1112857FA @default.
- Q90628323 P2093 Q90628323-42CB8BDB-093B-427F-B36D-D3789C48CC9B @default.
- Q90628323 P2093 Q90628323-75414866-6889-411F-981D-DF9A39FD4C5E @default.
- Q90628323 P2093 Q90628323-86BBD23F-F34A-4548-BD85-35C9054C8EB0 @default.
- Q90628323 P2093 Q90628323-9BEF08C9-8BCC-4F96-A332-46537A9BE9B6 @default.
- Q90628323 P2093 Q90628323-AD96225D-BB79-4DFD-A575-A5881D34C479 @default.
- Q90628323 P2093 Q90628323-BED9E78C-BF6B-43B7-96F2-767DA1FE7DD1 @default.
- Q90628323 P2093 Q90628323-CDE5E81C-7C24-45C8-A841-6CE41CA3B341 @default.
- Q90628323 P2093 Q90628323-FF2A892B-E806-440C-8EEE-0104E38D8689 @default.
- Q90628323 P2860 Q90628323-1252A836-8139-422E-8438-31C4D3574AC3 @default.
- Q90628323 P2860 Q90628323-16F90FB1-8C26-4A74-9703-56F176AFFAA7 @default.
- Q90628323 P2860 Q90628323-265B6F84-872C-4CFB-A7B8-9135979A695E @default.
- Q90628323 P2860 Q90628323-284524AD-753D-49B3-910E-D8ADD2850C17 @default.
- Q90628323 P2860 Q90628323-2880BAAE-6C4C-4341-91AD-DBC31E0A17A4 @default.
- Q90628323 P2860 Q90628323-298CAB18-001C-430C-B8AC-5130A9FC3767 @default.
- Q90628323 P2860 Q90628323-2EA3C696-CDE9-42B8-BFD9-15F99B8081B6 @default.
- Q90628323 P2860 Q90628323-3BD6DBE7-773F-4179-B71E-006F4AEBFAF6 @default.
- Q90628323 P2860 Q90628323-4960A1CA-4BE1-4978-8EC4-900486654484 @default.
- Q90628323 P2860 Q90628323-526EA557-E652-4E5D-8335-F0AEC8F1DE90 @default.
- Q90628323 P2860 Q90628323-535A2F85-5286-4CA0-A9F6-6CFA1157A912 @default.
- Q90628323 P2860 Q90628323-5CBAE304-9FC9-4233-8205-F2E1A5265674 @default.
- Q90628323 P2860 Q90628323-63641968-3A56-4752-B9F7-C615D82BF61B @default.
- Q90628323 P2860 Q90628323-7084C0EA-BD7F-4686-829A-4B19C0F5CFF8 @default.
- Q90628323 P2860 Q90628323-71045D91-F09F-447F-961E-5C591C4F9C88 @default.
- Q90628323 P2860 Q90628323-716B7E60-A16E-4249-9A2C-178101B90C33 @default.
- Q90628323 P2860 Q90628323-7555D63A-26F4-4903-9DEA-12FEDA148850 @default.
- Q90628323 P2860 Q90628323-7F01AA1B-BCC7-47BF-B1BA-9FFDB01FA5E7 @default.
- Q90628323 P2860 Q90628323-8C321A96-5D81-44AA-B32F-6A2D3D94A93C @default.
- Q90628323 P2860 Q90628323-98EEBA6D-E1F6-4C6F-8296-4C88035940E1 @default.
- Q90628323 P2860 Q90628323-9DB206F1-E9B6-46D2-97BB-5B4256FA4434 @default.
- Q90628323 P2860 Q90628323-A0E0CDF2-6F60-4028-9897-93C65CD076B9 @default.
- Q90628323 P2860 Q90628323-A959BBEB-A9CD-4C4F-8390-F84935FA610C @default.
- Q90628323 P2860 Q90628323-AE74C51E-4243-4302-A5CE-806AE4D7A6C4 @default.
- Q90628323 P2860 Q90628323-BB84240F-D947-4C25-87BE-C6EB2F7A852A @default.
- Q90628323 P2860 Q90628323-BF2D9594-4F46-40DA-A9F2-2E691842BC8F @default.
- Q90628323 P2860 Q90628323-CF70506D-7690-4687-9F49-26D8EF65E756 @default.
- Q90628323 P2860 Q90628323-DC9D27F6-5FF0-449E-BEE8-BBAF8F324137 @default.
- Q90628323 P2860 Q90628323-E0CE85F2-9DD9-42CF-BC09-1054437FC9B0 @default.
- Q90628323 P2860 Q90628323-EB14ECC0-774D-4EA5-BEA9-A218DA02E655 @default.
- Q90628323 P2860 Q90628323-FF144F56-7045-48DF-BDFD-C9A69B97BF92 @default.
- Q90628323 P304 Q90628323-44D97A32-F1BC-4B92-A94B-BD5F95060321 @default.
- Q90628323 P31 Q90628323-049BAD13-1975-4178-B3DA-BBCC96909CC3 @default.
- Q90628323 P356 Q90628323-A9846F65-DC99-4486-BDE2-5017F2A2BC53 @default.
- Q90628323 P407 Q90628323-DE0DF248-B63F-4AF0-B5C7-029C93D893ED @default.
- Q90628323 P433 Q90628323-6952C830-3EA0-40D5-B951-69D6D8472844 @default.
- Q90628323 P478 Q90628323-2644E7A4-EB86-47E0-BFB0-5B63B396DF8E @default.
- Q90628323 P577 Q90628323-B552FAC1-DE13-4E39-A640-8D9B5AC892C6 @default.
- Q90628323 P698 Q90628323-6C85F4BF-B57F-4606-BA7D-62D3ED3BD9F8 @default.
- Q90628323 P932 Q90628323-EA09DFAC-D7C3-409A-BAB2-509A55613C83 @default.
- Q90628323 P356 BJR.20190380 @default.
- Q90628323 P698 31600089 @default.
- Q90628323 P1433 Q15758529 @default.
- Q90628323 P1476 "Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort" @default.
- Q90628323 P2093 "Amit Joshi" @default.
- Q90628323 P2093 "Ganesh Bakshi" @default.
- Q90628323 P2093 "Kumar Prabhash" @default.
- Q90628323 P2093 "Rahul V Parghane" @default.
- Q90628323 P2093 "Sandip Basu" @default.
- Q90628323 P2093 "Sanjay Talole" @default.
- Q90628323 P2093 "Sharmila Banerjee" @default.
- Q90628323 P2093 "Sonam Suman" @default.
- Q90628323 P2860 Q27021674 @default.
- Q90628323 P2860 Q28253672 @default.
- Q90628323 P2860 Q29620155 @default.
- Q90628323 P2860 Q33334672 @default.
- Q90628323 P2860 Q33429398 @default.
- Q90628323 P2860 Q34024835 @default.
- Q90628323 P2860 Q34111641 @default.
- Q90628323 P2860 Q34682069 @default.
- Q90628323 P2860 Q36011267 @default.
- Q90628323 P2860 Q36135685 @default.
- Q90628323 P2860 Q37709519 @default.
- Q90628323 P2860 Q38970138 @default.
- Q90628323 P2860 Q39003089 @default.
- Q90628323 P2860 Q39173425 @default.
- Q90628323 P2860 Q39452544 @default.
- Q90628323 P2860 Q39930921 @default.
- Q90628323 P2860 Q40913769 @default.
- Q90628323 P2860 Q41904942 @default.
- Q90628323 P2860 Q41930832 @default.
- Q90628323 P2860 Q42140956 @default.
- Q90628323 P2860 Q42666028 @default.
- Q90628323 P2860 Q43577805 @default.
- Q90628323 P2860 Q44612245 @default.
- Q90628323 P2860 Q46157521 @default.
- Q90628323 P2860 Q47679260 @default.
- Q90628323 P2860 Q50259967 @default.